MARKET

SRPT

SRPT

Sarepta Therapeutics Inc
NASDAQ
18.23
-0.59
-3.14%
Opening 12:38 07/14 EDT
OPEN
18.85
PREV CLOSE
18.82
HIGH
18.85
LOW
18.08
VOLUME
712.17K
TURNOVER
--
52 WEEK HIGH
25.32
52 WEEK LOW
10.42
MARKET CAP
1.92B
P/E (TTM)
167.86
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SRPT last week (0706-0710)?
Weekly Report · 1d ago
2 Beaten-Down Stocks That Still Aren't Worth Buying
The Motley Fool · 2d ago
Analysts Offer Insights on Healthcare Companies: Forte Biosciences (FBRX), Sarepta Therapeutics (SRPT) and Opus Genetics (IRD)
TipRanks · 4d ago
Sarepta Therapeutics Price Target Cut to $20.00/Share From $23.00 by Piper Sandler
Dow Jones · 5d ago
Sarepta Therapeutics Is Maintained at Neutral by Piper Sandler
Dow Jones · 5d ago
Piper Sandler Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20
Benzinga · 5d ago
Tractor Supply downgrade, Five Below upgraded: Wall Street’s top analyst calls
TipRanks · 5d ago
Sarepta Therapeutics Raised to Outperform From Peer Perform by Wolfe Research
Dow Jones · 5d ago
More
About SRPT
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS.

Webull offers Sarepta Therapeutics Inc stock information, including NASDAQ: SRPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRPT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SRPT stock methods without spending real money on the virtual paper trading platform.